Kiniksa Pharmaceuticals International, plc Debt Securities, Available-for-sale, Unrealized Gain
Kiniksa Pharmaceuticals International, plc (KNSA) reported Debt Securities, Available-for-sale, Unrealized Gain of $1.00 thousand for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-04-25.
Discontinued › Income Statement › Other Income
us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain · last filed 2024-04-25
- Kiniksa Pharmaceuticals International, plc debt securities, available-for-sale, unrealized gain for the quarter ending 2024-03-31 was $1.00K, a 96.55% decline year-over-year.
- Kiniksa Pharmaceuticals International, plc debt securities, available-for-sale, unrealized gain for the quarter ending 2023-12-31 was $24.00K.
- Kiniksa Pharmaceuticals International, plc debt securities, available-for-sale, unrealized gain for the quarter ending 2023-09-30 was -$5.00K.
- Kiniksa Pharmaceuticals International, plc debt securities, available-for-sale, unrealized gain for the quarter ending 2023-06-30 was -$18.00K.
| Period end | Debt Securities, Available-for-sale, Unrealized Gain 3 month | Debt Securities, Available-for-sale, Unrealized Gain 6 month | Debt Securities, Available-for-sale, Unrealized Gain 9 month | Debt Securities, Available-for-sale, Unrealized Gain 12 month |
|---|---|---|---|---|
| 2024-03-31 | $1.00K 10-Q · filed 2024-04-25 | $25.00K derived: sum of 2 quarters · filed 2024-04-25 | $20.00K derived: sum of 3 quarters · filed 2024-04-25 | $2.00K derived: sum of 4 quarters · filed 2024-04-25 |
| 2023-12-31 | $24.00K derived: 10-Q 12 month − 10-Q 9 month · filed 2024-04-25 | $19.00K derived: sum of 2 quarters · filed 2024-04-25 | $1.00K derived: sum of 3 quarters · filed 2024-04-25 | $30.00K 10-Q · filed 2024-04-25 |
| 2023-09-30 | -$5.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | -$23.00K derived: sum of 2 quarters · filed 2023-11-02 | $6.00K 10-Q · filed 2023-11-02 | |
| 2023-06-30 | -$18.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-01 | $11.00K 10-Q · filed 2023-08-01 | ||
| 2023-03-31 | $29.00K 10-Q · filed 2023-05-04 | |||
| 2022-12-31 | $9.00K 10-Q · filed 2023-11-02 |